Yearly versus usual ocrelizumab infusions in active multiple sclerosis
Compares yearly and usual ocrelizumab dosing in active multiple sclerosis.
Key facts
- Who runs it
- Hopital Fondation Adolphe De Rothschild
- Where
- Bron, Creteil Cedex, Gonesse, Grenoble Cedex 09, Limoges Cedex 1, Nice, Paris, Paris Cedex 13, Poissy, Strasbourg Cedex 2, and Suresnes, FranceSee the 11 sites
- Trial code
- Registry title
- For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment on the absence of radiological disease activity at 2 years: a multicentre randomised controlled non-inferiority trial
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 244 people, planned
- Started
- 9 Nov 2023
- Expected to end
- 26 May 2027
- Type of study
- Interventional
- Record updated
- 7 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active multiple sclerosis who have had at least 2 years of ocrelizumab. It compares one infusion a year with one infusion every 6 months.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Relapsing remitting or secondarily progressive MS when anti-CD20 treatment began, with a relapse or MRI activity in the year before. No relapse for at least 18 months. EDSS between 0 and 6 inclusive.
- Earlier treatment
- Coming for at least a 4th semester cycle of ocrelizumab. Started ocrelizumab or rituximab (anti-CD20) treatment earlier.
Main reasons for not taking part
- Primary progressive MS
- Pregnant, or planning a pregnancy within 3 years
- Already receiving ocrelizumab doses spaced 9 months or more apart
- Cannot continue ocrelizumab (for example hypersensitivity, active infection, cancer, severe immune deficiency)
- Cannot have an MRI or contrast injection
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Patient 18 years or older
- Coming for a 4th semester cycle of ocrelizumab (at least)
- Requires follow-up cerebral-medullary MRI as part of care
- Who had relapsing remitting or secondarily progressive MS at the time of initiation of anti-CD20 (ocrelizumab or rituximab) therapy : relapse or radiological activity in the year priori to initiation of high-efficacy treatment
- No relapse for at least 18 months
- EDSS between 0 and 6 inclusive
- Having received information about the study and having signed a consent to participate in the study
- Knowledge of the French language
- Affiliated or beneficiary to a social security scheme
Who cannot take part
- Patients already receiving routine spacing ≥ 9 months of ocrelizumab doses
- Contra-indication to continued treatment with ocrelizumab (hypersensitivity reaction, ongoing active infection, development of a malgnant disease since the previous inhection, development of a severe immune deficiency)
- Subjects with severe or uncontrolled symptoms of renal, hepatic, haematological, gastrointestinal, pulmonary, psychiatric or cardiac disease or any uncontrolled intercurrent disease
- Clinical forms of primary progressive multiple sclerosis (PP)
- Pregnant woman
- Planning a pregnancy within 3 years
- Contra-indication to MRI
- Contra-indication to the injection of contrast products
- Patient under legal protection measure
- Patients of childbearing potential who do not wish to use effective contraception during their participation and at least 4 months after the last dose (oral commitment of the patient recorded in the medical file by the investigator)
Where in France
- Hospices Civils de LyonBron, FranceTaking people
- Assistance Publique Hopitaux De ParisCreteil Cedex, FranceTaking people
- Centre Hospitalier GeneralGonesse, FranceTaking people
- Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 09, FranceTaking people
- Centre Hospitalier Et Universitaire De LimogesLimoges Cedex 1, FranceTaking people
- Centre Hospitalier Universitaire de NiceNice, FranceTaking people
- Hopital Fondation Adolphe de RothschildParis, FranceTaking people
- Assistance Publique Hopitaux De ParisParis Cedex 13, FranceTaking people
- Centre Hospitalier Intercommunal De Poissy Saint GermainPoissy, FranceTaking people
- Les Hopitaux Universitaires De StrasbourgStrasbourg Cedex 2, FranceTaking people
- Hospital FochSuresnes, FranceTaking people
About the trial
What the trial wants to find out
To compare the efficacy of a treatment plan with annual administrations of ocrelizumab versus a conventional treatment plan with semi-annual administrations, on the absence of radiological disease activity at 2 years, in patients with active MS treated for at least 2 years with ocrelizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment on the absence of radiological disease activity at 2 years: a multicentre randomised controlled non-inferiority trial
- Plain-language title
- Yearly versus usual ocrelizumab infusions in active multiple sclerosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 7 April 2026